Modulation of methylglyoxal-triggered oxidative damage and apoptosis in human osteoblasts by metformin, berberine, and genistein

Read full text Summarise with VIRAT
Authors: Alyaa Mahmood Al-Khateeb, Suhaila Abd Muid, Gabriele Ruth Anisah Froemming
Cited by: 0
References: 48

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Bone fragility in diabetes is linked to redox imbalance and advanced glycation end products (AGEs). Methylglyoxal (MGO), a reactive carbonyl compound and precursor of AGEs, complicates the pathogenesis of diabetes mellitus and oxidative stress. Metformin lowers the AGEs level. Genistein and berberine decrease MGO levels and inhibit AGE formation. This study investigates the individual and combinatorial effects of metformin, berberine, and genistein on osteoblast-treated MGO in terms of apoptosis and oxidative stress. Human foetal osteoblast cells (hFOB 1.19) were incubated with MGO for 24 hours and treated with metformin, berberine, genistein, and combinations of these compounds. The cells were assessed for apoptosis, AGE levels, oxidative stress markers, and the polymerization status of actin and tubulin fibers. Incubation with metformin, berberine, or genistein alone showed that these compounds significantly reduced apoptotic cells (26.16%, 31.83%, and 41.83%, respectively) compared to MGO alone(p

Fields of Study & Subjects

Advanced Glycation End Products research Bone Metabolism and Diseases Metabolism Diabetes and Cancer

Publication details

Journal / source
Asia-Pacific Journal of Molecular Biology and Biotechnology
Pages
155–155
Publication date
28 March 2026
Language
EN